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Urinary procoagulant and fibrinolytic activity in human glomerulone-
phritis. Relationship with renal function. Fibrin deposition in kidney is a
common event in some forms of human and experimental glomerulo-
nephritis, and is thought to result from local activation of blood
coagulation and/or impaired removal by the fibrinolytic system. We
studied the urinary procoagulant and fibrinolytic activities in 46 patients
with renal disease (26 with IgA nephritis, 13 with other forms of
glomerulonephritis and 7 with non-inflammatory kidney disease) and in
15 matched healthy subjects, as possible indicators of the coagulation-
fibrinolysis balance in kidney. Procoagulant activity was slightly but not
significantly increased in patients with serum creatinine levels higher
than 1.5 mg/dl (group II) as compared with patients with normal
creatinine (group I) and controls. It was identified as tissue factor by
biological criteria (dependence on factor VII). Fibrinolysis studies
showed that both plasminogen activator activity and urokinase antigen
were significantly lower in group II than in group I patients and controls
(P < 0.0005). Reduced fibrinolytic activity in patients' urine was due to
decreased excretion of urokinase since no inhibitor was detected by
both fibrin autography and functional assay. No differences were found
between patients and controls in plasma fibrinolytic activity, plasmino-
gen activator inhibitor, and procoagulant activity of blood monocytes.
The urinary changes in severe renal disease may reflect an unbalance of
the coagulation-fibrinolysis equilibrium in kidney and might be of
pathogenetic and clinical relevance.
Activation of blood coagulation and fibrin deposition are
common events in some forms of human and experimental
glomerulonephritis and are thought to play a major pathogenetic
role in the development and the progression of the disease
[1—61. The mechanisms underlying these phenomena, however,
remain unclear. Glomeruli from animals with different forms of
renal disease express high levels of procoagulant activity (PCA)
at the time that glomerular fibrin deposition occurs [7—101. This
has been attributed by most investigators to the production of
PCA by infiltrating macrophages [7, 8, 11, 12], although the
involvement of intrinsic glomerular cells (endothelial, mesan-
gial) cannot be excluded [13]. Whatever the cell type involved,
augmented glomerular PCA has been proposed as an important
mechanism triggering the coagulation cascade in the kidney.
The clinical relevance of these findings is highlighted by the
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recent demonstration of a marked increase in PCA of glomeruli
from patients with proliferative glomerulonephritis [14].
The deposition of fibrin in the kidney may result not only
from pathological activation of blood coagulation but also, or
alternatively, from impaired removal by the fibrinolytic system.
This concept stems mainly from animal studies showing a
reduced local fibrinolytic activity in certain forms of renal injury
[15—171. Interestingly, Miura et al [18] reported the deposition
of c2-plasmin inhibitor in glomeruli of patients with IgA
nephropathy (IgAN) with resultant reduced local fibrinolysis.
Altogether these findings support the view that fibrin deposi-
tion in kidney results from local changes in the coagulation-
fibrinolysis balance.
Wiggins, Glatfelter and Brukman [81 reported that, in rabbits
with nephrotoxic nephritis, PCA not only increased in glomer-
uli, but also appeared in urine during the development of
glomerular injury, suggesting that urinary changes in clotting
and/or fibrinolytic parameters might represent possible indica-
tors of the coagulation-fibrinolysis balance in kidney.
This study was designed to evaluate the urinary procoagulant
and fibrinolytic activities in patients with different forms of
glomerulonephritis, in relation with the severity of the disease.
Methods
Patients
Forty-six patients with renal diseases, 18 females, aged 17 to
69 years (mean: 40 years) were studied after informed consent
had been obtained. Twenty-six patients had IgA nephritis, 13
non-IgA glomerulonephritis (6 mesangial proliferative glomeru-
lonephritis without IgA deposits, 4 mesangiocapillary glomeru-
lonephritis, 1 membranous glomerulonephritis, 1 focal and
segmental glomerulosclerosis, 1 minimal change disease), 7
non-inflammatory kidney disease (5 polycystic kidney disease,
2 nephroangiosclerosis). Diagnosis was made by clinical and
laboratory criteria and was confirmed by renal biopsy in all but
the five patients with polycystic kidney disease. The renal
histologic lesions in patients with IgAN were classified accord-
ing to the system of Lee et al [191: grade I, minimal changes, N
= 3; grade II, minor changes, N = 12; grade III, focal and
segmental glomerulonephritis, N = 5; grade IV, diffuse mesan-
gial proliferative glomerulonephritis, N 6. All patients were
divided into two groups according to the serum creatinine
levels: group I, creatinine l.5 mg/dl (mean SD, 1.01 0.18,
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N = 30); group II, creatinine >1.5 mg/dl (mean SD, 3.39
1.97, N = 16). Fifteen matched healthy subjects served as
control group. Neither patients nor controls had taken steroids,
immunosuppressive drugs, anticoagulants or antiplatelet
agents.
In all patients and controls, nine-hour urine collections were
made in the morning. The urine samples were centrifuged at
12,000 RPM (Eppendorf centrifuge) for 10 minutes and dialyzed
against 0.02 M Tris, 0.15 M NaCI, pH 7.4 for 16 hours at 4°C.
Functional assays were performed immediately after dialysis
whereas, for immunological assays, aliquots of the samples
were frozen at —20°C and thawed just before testing. In some
experiments, undialyzed urines were tested in parallel.
Blood samples were collected on trisodium citrate (0.015 M
final concentration). Platelet-poor plasma was prepared from an
aliquot of blood by centrifugation (20 mm at 1200 x g) at 4°C,
and tested within one hour.
Fibrinolysis studies
Plasma plasminogen activator (PA) activity was measured on
the euglobulin fraction by the fibrin plate method [20, 211 and
expressed in t-PA equivalent units. Plasminogen activator in-
hibitor (PAl) activity in plasma was assayed with an amidolytic
method as described [221. Two-chain melanoma t-PA and
purified human plasminogen were kindly provided by Dr. D.
Collen, Leuven, Belgium. The chromogenic substrate S-225l
was purchased from Ortho Diagnostic Systems, Milano, Italy.
Fibrinolytic activity of urine was evaluated by the fibrin plate
method using 20 jsl of undiluted sample, and expressed in
urokinase (u-PA) units by reference to a purified u-PA prepa-
ration. t-PA and u-PA related antigens in urine were determined
by commercial ELISA kits (Ortho and Cabru, Milano, Italy,
respectively). SDS-PAGE of urine was carried out on mini slab
gels (Mini Protean II, Bio Rad, Richmond, California, USA)
using resolving gels of 7.5% acrylamide and stacking gels of 4%
acrylamide. Fibrin autography of these gels was performed on
plasminogen-rich fibrin films [23].
Coagulation studies
Mononuclear cells were isolated from citrated blood by the
Ficoll.-Hypaque (Lymphoprep, Nyegaard, Oslo. Norway) gra-
dient technique [24], as reported [251. Final cell preparations
contained more than 97% mononuclear cells and less than one
platelet per nucleated cell. Monocytes, identified by esterase
staining, made up 12 to 26% (mean 16%) and 14 to 29% (mean
18%) of the mononuclear cells in controls and patients respec-
tively. Cell viability always exceeded 96%. PCA of mononu-
clear cells was studied immediately after isolation and after
incubation with endotoxin (1 jgIml, Escherichia coli Olll:B4,
LPS, W, Difco Lab., Detroit, Michigan) for four hours at 37°C
[25]. Assays were performed with cells disrupted by triple
freezing and thawing. PCA was evaluated by a one-stage
clotting assay using the following test system: 0.1 ml cell sample
or dialyzed urine, 0.1 ml normal plasma, 0.1 ml CaCI2 (0.025 M).
Results were expressed in arbitrary units (U) by comparison of
the clotting times of test samples with a standard curve of
clotting times produced by dilutions of a human brain throm-
boplastin suspension [25]. One hundred units of thromboplastin
caused normal plasma to clot in 63 seconds. There was a linear
relationship between thromboplastin 0.2 to 100 U and clotting
times in a Log-Log plot. Using thromboplastin dilutions giving
clotting times comparable to those of urine samples, the intra-
and inter-assay variation coefficients of PCA clotting test were
10% and 16%, respectively. To examine the functional charac-
teristics of PCA, clotting assays were performed using plasma
substrates selectively deficient in single coagulation proteins
[25].
Statistical methods
Results were calculated for one minute urine excretion.
Difference among groups was evaluated by the Kruskal-Wallis
test; when required, comparison between groups was made by
the Mann-Whitney test using the Bonferroni's correction (level
of statistical significance: P < 0.05/number of comparisons).
Spearman rank order analysis or linear regression analysis were
used when appropriate.
Results
Studies in urine
Urinary PCA was not significantly different in patients and
controls, although a trend towards higher levels was observed
in patients with increased serum creatinine (Fig. 1). Urine
samples with the highest PCA were selected for biological
characterization of the activity. Samples from both patients and
controls were equally active in normal and factor IX-deficient
plasma (patients: 7.5 3.2 vs. 7.3 3.1 U/mI, N = 10; controls:
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Fig. 1. Urinary PCA in controls and in patients grouped according to
the serum creatinine levels. Group I (GR I): serum creatinine 1.5
mg/dl; group II (GR II): serum creatinine >1.5 mg/dl.
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Fig. 2. Plasminogen activator activity in the urine of controls, group!
(GR I) and group II (GR II) patients.
5.7 2.3 vs. 5.6 2.3 U/mI, N = 6), but expressed almost no
activity in factor VII- or factor X-deficient plasma (<0.2 UIml)
suggesting that the bulk of urinary PCA had the characteristics
of tissue factor.
Urinary fibrinolytic parameters are shown in Figures 2 and 3.
Both plasminogen activator activity and u-PA related antigen
were much lower in patients with high creatinine levels (group
II) than in patients with normal creatinine (group I) and controls
(P < 0.0005). In most group II patients both fibrinolytic
parameters were below the lowest values of controls and group
I patients. However, no significant correlation was found in
each group between fibrinolytic parameters and serum creati-
nine (P always higher than 0.3, by Spearman rank order
analysis). A strong correlation was found between plasminogen
activator activity and u-PA antigen (r = 0.95 by linear regres-
sion analysis), indicating that both in controls and patients,
urinary fibrinolytic activity is due to u-PA. t-PA antigen in urine
was low (1 to 5 ng/min) and did not differ among groups.
It has been reported that dialysis of urine causes the appear-
ance of an inhibitor that binds to urokinase [26]. To rule out that
reduction of fibrinolytic activity in group II patients was due to
this inhibitor, PA activity was measured also in undialyzed
urine. While in controls and group I patients undialyzed sam-
ples displayed higher activity than dialyzed urines (mean sr:
10.8 5.5 vs. 7.7 5.2 U/mm and 10.2 5.1 vs. 7.0 4.6
U/mm, respectively), in group II patients the dialysis procedure
did not influence the results (0.44 0.41 vs. 0.39 0.40 U/mm),
suggesting that reduction in fibrinolytic activity was due to a
decrease in u-PA content. This is supported by the SDS-PAGE
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of urine samples followed by fibrin autography, a technique that
visualizes the molecular forms of plasminogen activator, includ-
ing activator-inhibitor complexes. As shown in Figure 4, a
single band comigrating with purified u-PA was visible in
undialyzed samples, whereas one or two additional bands in the
90 kD region appeared after dialysis. In contrast, in the urine of
group II patients visible lysis zones were observed neither
before nor after dialysis. To further rule out the presence of
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Fig. 3. u-PA antigen levels in the urine of controls, group I (GR I) and
group II (GR II) patients.
Fig. 4. Representative fibrin autography of urine samples from con-
trols (C), group 1(1) and group 11(11) patients. A. Undialyzed samples.
B. Dialyzed samples. Purified u-PA was run in parallel for comparison.
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Table 1. Blood laboratory parameters in controls and in group I and
group II patients.
Controls
(N = 12)
Group I(N = 20)
Group H(N = 14)
Monocyte PCA
U/JO5 cells
Basala 2.8 0.6 2.4 0,5 2.9 0.8
Induce&' 625 72 590 60 684 77
PA activity
U/mi 3.9 0.6 4.2 0.7 4.2 0.6
PAl activity
U/mi 8.9 1.9 8.4 2.1 9.1 2.2
a PCA measured on freshly isolated cells
b PCA measured on cells incubated for 4 hours at 37°C in the
presence of endotoxin (1 sg/ml).
u-PA inhibitor activity, patients' urine was mixed with increas-
ing amounts of u-PA (from 0.5 to 2 lU/mi, final concentration)
and incubated at 37°C for 30 minutes. Functional assay and
fibrin autography showed that u-PA activity was fully recovered
from these mixtures and that no u-PA inhibitor complexes were
formed (not shown). When fibrinolytic activity was analyzed
according to the type of renal disease, no difference was
observed among patients with IgAN, those with non-IgA gb-
merulonephritis or non-inflammatory kidney disease and con-
trols (P 0.07),
In the subgroup of patients with IgAN, Spearman rank order
analysis revealed a significant correlation between the histolog-
ical grading (grade Ito IV) and urinary PA activity (r = —0.55,
P < 0.005) or u-PA antigen (r =
—0.56, P < 0.005).
Fibrinolysis studies were repeated in 18 patients and 9
controls at least one month later. The results obtained were well
comparable with those observed in the first determination (y =
0.93x — 0.23, r = 0.85, by linear regression analysis).
Studies on peripheral blood
Both basal PCA of peripheral blood monocytes and PCA
generated in vitro by these cells in response to endotoxin were
not significantly different in patients and controls. Likewise, no
difference among groups was found in the plasma levels of
plasminogen activator and PAl activities (Table 1).
Discussion
PCA is known to occur in normal human urine and has been
reported to be thromboplastin-like by biological criteria, though
differing from brain thromboplastin in the molecular weight [27,
28]. Studies of urinary PCA in kidney disorders have been
limited so far to animal models with rather conflicting results. In
rabbit nephrotoxic nephritis, Matsumura, Hutt and von Kaulla
[29] reported that PCA disappeared from urine during the onset
of glomerulonephritis. More recently, in the same experimental
model, Wiggins, Glatfelter and Brukman [8] found a marked
increase in the urinary excretion of PCA during the develop-
ment of glomerular injury.
In this study we observed a slightly increased PCA in the
urine of patients with high serum creatinine levels which,
however, just failed to achieve statistical significance. PCA was
similar to tissue factor by functional criteria (dependence on
factor VII). It should be remembered that all urines were
dialyzed before testing since there was a marked difference in
osmolarity among samples. Due to the relatively poor stability
of PCA in urine [30], the possibility that the results had been
partly affected by the dialysis procedure cannot be excluded.
The main finding in this study was that both plasminogen
activator activity and u-PA antigen were markedly reduced in
the urine of patients with impaired renal function. Interestingly,
there was almost no overlapping between values observed in
the latter group and those of patients with normal creatinine and
controls. Reduction of urinary fibrinolytic activity is due to
decreased excretion of u-PA and not to the presence or increase
of a u-PA inhibitor, as indicated by the following observations.
First, a strong correlation was found between PA activity and
u-PA antigen (r = 0.88 in group II patients). Second, the mean
specific activity of u-PA in urine was similar to that reported for
pure two-chain u-PA (100,000 lU/mg). Third, by zymographic
analysis visible lysis areas were observed neither in the 54 kD
region (corresponding to free u-PA) nor in the 90 kD region
(corresponding to activator-inhibitor complexes) even after
dialysis, a procedure known to cause the appearance of a u-PA
inhibitor [26]. Finally, addition of u-PA to patients' urine did
not result in inhibition of activity or binding to a urinary
component.
The absence of significant amounts of single-chain u-PA (with
lower specific activity) in the urine of our patients and controls
is due to the fact that, in order to perform the functional assay,
collection was made without inhibitors that prevent conversion
of single chain u-PA to the two chain form.
The mechanisms leading to reduced urinary u-PA in our
patients remain unknown. These changes, however, may reflect
an impairment of the fibrinolytic capacity at kidney level. As a
matter of fact, Saito et al [31] reported that, in proliferative or
membranous glomerulonephritis, urinary levels of u-PA were
lower in patients with positive intraglomerular fibrin.
Previous studies have shown that peripheral blood mono-
cytes from patients with certain forms of glomerulonephritis,
particularly lupus nephritis, express high levels of PCA and that
such increased PCA is related to the severity of the disease [32].
In this study we did not find significant differences in monocyte
PCA among groups. Moreover, results were similar in patients
and controls when plasma fibrinolytic activity and PAl activity
were examined, suggesting that abnormalities in laboratory
coagulation and fibrinolysis parameters can hardly be detected
at systemic level.
In conclusion, in the urine of patients with severe glomerular
disease there are profound modifications in the mechanism
devoted to fibrin removal, that is, markedly reduced fibrinolytic
potential. This finding, coupled with the observation that in the
same patients urinary PCA is normal or slightly increased
suggests that the coagulation-fibrinolysis balance in kidneys is
shifted towards fibrin deposition. Since fibrin is an important
mediator of glomerular injury, the described changes could be
of pathogenetic relevance in the development and, especially,
in the progression of the disease. It is noteworthy that impaired
urinary fibrinolysis can clearly discriminate between patients
with altered renal function and patients with normal renal
function, as evaluated by the serum creatinine levels. This
suggests that the measurement of fibrinolytic parameters in
urine might be of clinical relevance.
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